News
10 February 2012 - ACTA threatens access to medicines and public health by: (1) dissuading generic producers from trading their medicines - healthcare systems and consumers will be left to pay higher prices; (2) aiming to set a global standard that would apply high IP standards to developing countries that currently rely on affordable generic medicines to meet health needs; (3) including a broad definition of trademark infringement that can catch legitimate generic medicines. These provisions have already led to the detainment of generics in transit to developing countries.
Background
World Trade Organization (WTO) Agreement on Trade Related Aspects of Intellectual Property (TRIPS) (1994)Council Conclusions on EU Role in Global Health (2010)
EU Communication on EU Role in Global Health (2010)
Doha Declaration on TRIPS and Public health (2001)
World Health Organization (WHO) Briefing Note: Data Exclusivity and Other TRIPS plus Measures (2006)
EU Parliament Resolution on TRIPS agreement and Access to Medicines (2007)
Publications
Sep 2011Policy Debrief - European Union & Andean Community Trade Agreements, Intellectual Property & Public Health (EN) (ES)
Sep 2011
Chronology - The EU-Andean Community Trade Agreements & Access to Medicines
June 2011
Trans Atlantic Consumer Dialogue Resolution on Innovation and Access to Medical Technologies
May 2011
The Intellectual Property and Investment Chapters of the EU-India FTA: Implications for Health
Apr 2011
Protecting Access to Medicines: The India and Mercosur Trade Agreements
Policy Briefs & Reports
October 2009 Joint HAI Europe - Oxfam Report Trading Away Access to Medicines (EN) (FR) (ES)
November 2009 IFARMA Impact Study on EU-Andean Trade Agreement in Peru (EN) (ES)
June 2009 IFARMA Impact Study on EU-Andean Trade Agreement in Colombia (EN)
December 2010 IFARMA Impact Study on EU-Andean Trade Agreement in Ecuador (ES)